Knights of Columbus Asset Advisors’s Viking Therapeutics VKTX Stock Holding History

Knights of Columbus Asset Advisors’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-18,459	Closed	-$489K	–	410
2025 Q2	$489K	Sell	18,459 -270	-1%	-$7.11K	0.03%	280
2025 Q1	$452K	Buy	18,729 +497	+3%	+$15.7K	0.03%	266
2024 Q4	$734K	Buy	18,232 +48	+0.3%	+$2.74K	0.05%	253
2024 Q3	$1.15M	Sell	18,184 -24,070	-57%	-$1.41M	0.08%	234
2024 Q2	$2.24M	Buy	42,254 +418	+1%	+$27.4K	0.15%	199
2024 Q1	$3.43M	Sell	41,836 -39,851	-49%	-$1.77M	0.25%	145
2023 Q4	$1.52M	Buy	81,687 +41,130	+101%	+$538K	0.1%	242
2023 Q3	$449K	Buy	40,557 +1,226	+3%	+$17.5K	0.04%	273
2023 Q2	$638K	Buy	+39,331	New	+$824K	0.06%	265

Other funds holding VKTX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Knights of Columbus Asset Advisors's VKTX Position: Q3 2025 in Review

Knights of Columbus Asset Advisors sold out of Viking Therapeutics (VKTX) in Q3 2025, closing a stake of 18,459 shares — an estimated $489K sold.

Knights of Columbus Asset Advisors first reported a position in VKTX in Q2 2023 and held it in 9 quarters. The position peaked at $3.43M in Q1 2024. 371 funds tracked by Wall St. Rank hold VKTX as of Q3 2025.

Knights of Columbus Asset Advisors reported no remaining Viking Therapeutics position as of Q3 2025 after selling out during the quarter.
Knights of Columbus Asset Advisors sold 18,459 Viking Therapeutics shares in Q3 2025, an estimated $489K.
Knights of Columbus Asset Advisors first reported a position in Viking Therapeutics in Q2 2023 and held it in 9 quarters.
Knights of Columbus Asset Advisors's Viking Therapeutics position peaked at $3.43M in Q1 2024.
371 funds tracked by Wall St. Rank held Viking Therapeutics as of Q3 2025.

Based on Knights of Columbus Asset Advisors's 13F filing for Q3 2025, filed 3 Nov 2025.